Education
About Us
Working with TipRanks
Follow Us
Interpace Diagnostics Group (IDXG)
OTHER OTC:IDXG
IDXG Stock Chart & Stats
$0.94
$0.00(0.00%)
At close: 4:00 PM EST
$0.94
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.44 - $1.91
Previous CloseN/A
Volume34.00
Average Volume (3M)11.58K
Market Cap
$7.97M
Enterprise Value$7.63M
Total Cash (Recent Filing)$1.42M
Total Debt (Recent Filing)$864.00K
Price to Earnings (P/E)6.6
Beta1.24
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding4,428,539
10 Day Avg. Volume15,402
30 Day Avg. Volume11,583
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-5.34
Price to Sales (P/S)0.25
P/FCF Ratio3.14
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue0.18
Enterprise Value/Gross Profit0.28
Enterprise Value/Ebitda1.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationSustained recovery in operating and free cash flow reduces dependence on external financing and supports reinvestment in lab automation, sales, and R&D. Strong cash conversion gives management flexibility to fund growth initiatives and withstand industry cyclicality over the next several quarters.
High And Expanding MarginsRobust gross and operating margins indicate durable unit economics in the thyroid testing franchise, enabling scalable profitability as volumes rise. Higher margins support investment capacity and improve resilience against pricing or reimbursement pressures common in diagnostics.
Simplified Capital Structure And DeleveragingEarly loan repayment and conversion of preferred shares into common reduce interest burden and complexity, improving financial flexibility. A cleaner balance sheet enhances ability to invest commercially and pursue an uplisting, broadening capital access and supporting medium‑term growth plans.
Bears Say
Negative Shareholders' EquityPersisting negative equity signals historical losses or prior financing that can limit access to capital and strategic options. Even with debt reduction, negative equity can constrain covenants, lender confidence, and limit ability to absorb shocks or fund larger strategic investments over the coming months.
Concentration Of Revenue In One FranchiseA full pivot to thyroid testing increases operational and market risk from single‑product concentration. Adverse reimbursement, competitive entrants, or regulatory changes in thyroid diagnostics could materially impact revenue and growth durability without diversified product lines.
High Insider/private Equity Ownership ConcentrationTwo firms controlling a large majority of shares can expedite strategic moves but may limit minority shareholder influence and prioritize sponsor objectives. This concentration raises governance and liquidity risks and could lead to future dilution or strategic decisions misaligned with public investors.
Interpace Diagnostics Group News
IDXG FAQ
What was Interpace Diagnostics Group’s price range in the past 12 months?
Interpace Diagnostics Group lowest stock price was $0.44 and its highest was $1.91 in the past 12 months.
What is Interpace Diagnostics Group’s market cap?
Interpace Diagnostics Group’s market cap is $7.97M.
When is Interpace Diagnostics Group’s upcoming earnings report date?
Interpace Diagnostics Group’s upcoming earnings report date is May 07, 2026 which is in 75 days.
How were Interpace Diagnostics Group’s earnings last quarter?
Interpace Diagnostics Group released its earnings results on Nov 12, 2025. The company reported $0.033 earnings per share for the quarter, beating the consensus estimate of N/A by $0.033.
Is Interpace Diagnostics Group overvalued?
According to Wall Street analysts Interpace Diagnostics Group’s price is currently Overvalued.
Does Interpace Diagnostics Group pay dividends?
Interpace Diagnostics Group does not currently pay dividends.
What is Interpace Diagnostics Group’s EPS estimate?
Interpace Diagnostics Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Interpace Diagnostics Group have?
Interpace Diagnostics Group has 4,428,539 shares outstanding.
What happened to Interpace Diagnostics Group’s price movement after its last earnings report?
Interpace Diagnostics Group reported an EPS of $0.033 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3%.
Which hedge fund is a major shareholder of Interpace Diagnostics Group?
Currently, no hedge funds are holding shares in IDXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Interpace Diagnostics Group
Interpace Diagnostics Group (IDXG) is a biotechnology company specializing in developing and commercializing molecular diagnostic tests for cancer and other diseases. The company operates primarily in the healthcare sector, focusing on providing innovative diagnostic solutions that aid in the early detection and management of cancer, particularly in the gastrointestinal field. IDXG's core products include a portfolio of molecular tests designed to improve diagnostic accuracy and inform treatment decisions for patients, thereby enhancing patient outcomes.
Technical Analysis
―
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
Mainz Biomed B.V.
―
bioAffinity Technologies, Inc.
―